Stay updated on Pembrolizumab for Desmoplastic Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Desmoplastic Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab for Desmoplastic Melanoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the loaded study record content with a minimal header and footer, indicating access is blocked.SummaryDifference17%

- Check37 days agoChange DetectedThe revision label was updated from v3.6.5 to v3.6.6, indicating a software update. There are no visible changes to study content or user-facing functionality.SummaryDifference0.0%

- Check59 days agoChange DetectedThe page now reflects an updated platform revision to v3.6.5, indicating an underlying system update; user-facing study information remains unchanged.SummaryDifference0.0%

- Check73 days agoChange DetectedThe page revision tag changed from v3.6.3 to v3.6.4, indicating an updated version of the page. This update appears to be a backend/content-management change with no substantive modification to the trial details.SummaryDifference0.0%

- Check87 days agoChange DetectedNew update timestamps were added and older ones removed, reflecting the latest revision history of the study record.SummaryDifference0.1%

- Check95 days agoChange DetectedThree new study sites were added (CommonSpirit Saint Joseph Hospital Bardstown; CommonSpirit Saint Joseph Medical Center East Lexington; CommonSpirit Saint Joseph Hospital London), and three existing sites were removed (Flaget Memorial Hospital; Saint Joseph Hospital East; Saint Joseph London). The page includes a new revision tag (v3.6.3).SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for Desmoplastic Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Desmoplastic Melanoma Clinical Trial page.